{"title":"[Duration of efficiency of pertussis immunoglobulin in the passive protection tests in mice (author's transl)].","authors":"S Sabin, M Schwanig, W Schneider","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The prophylactical effect of human anti-Pertussis immunoglobulin was shown in a passive protection test in mice over a time of 9 days, which is more than three times the half live time. In the agglutination test one could find a half life time of 64.7 hours; in the neutralisation test, which is the only valuable for the clinical effect, we could find an average value of half life time of 51.6 hours. We found a nearly parallel decrease in both titers. In the view of our results we discussed former clinical trials and the prospects for a future use of anti-Pertussis immunoglobulins in prophylaxis and therapy; in both fields only those preparations should be used, which are tested for clinical efficiency in a neutralisation test.</p>","PeriodicalId":23929,"journal":{"name":"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie","volume":"249 2","pages":"254-60"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zentralblatt fur Bakteriologie. 1. Abt. Originale. A: Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The prophylactical effect of human anti-Pertussis immunoglobulin was shown in a passive protection test in mice over a time of 9 days, which is more than three times the half live time. In the agglutination test one could find a half life time of 64.7 hours; in the neutralisation test, which is the only valuable for the clinical effect, we could find an average value of half life time of 51.6 hours. We found a nearly parallel decrease in both titers. In the view of our results we discussed former clinical trials and the prospects for a future use of anti-Pertussis immunoglobulins in prophylaxis and therapy; in both fields only those preparations should be used, which are tested for clinical efficiency in a neutralisation test.